Importance The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-
like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or …

Importance Weight loss improves cardiometabolic risk factors in people with overweight or
obesity. Intensive lifestyle intervention and pharmacotherapy are the most effective …

Background Weight reduction is essential for improving health outcomes in people with
obesity and type 2 diabetes. We assessed the efficacy and safety of tirzepatide, a glucose …

Background Malnutrition and dehydration are widespread in older people, and obesity is an
increasing problem. In clinical practice, it is often unclear which strategies are suitable and …

Obesity is an epidemic and a public health threat. Medical weight management remains one
of the options for the treatment of excess weight and recent advances have revolutionized …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

Background We assessed the efficacy and safety of the oral glucagon-like peptide-1
analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of …

Despite decades of unequivocal evidence that waist circumference provides both
independent and additive information to BMI for predicting morbidity and risk of death, this …

Aims Obesity is a global health problem, associated with significant morbidity and mortality,
often due to cardiovascular (CV) diseases. While bariatric surgery is increasingly performed …

The effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like
peptide-1 receptor agonist, on weight reduction after successful intensive lifestyle …